Table 4.
ORR and CR in patients treated with atezolizumab plus bevacizumab
| N (%) | p value | Odds ratio | N (%) | p value | Odds ratio | ||
|---|---|---|---|---|---|---|---|
|
Decreased appetite ORR No ORR |
49 (27.8%) 127 (72.1%) |
0.87 | 0.97 |
Decreased appetite CR No CR |
1 (0.6%) 175 (99.4%) |
0.02 | 9.71 |
|
No decreased appetite ORR No ORR |
176 (27.2%) 471 (72.8%) |
(0.67–1.40) |
No decreased appetite CR No CR |
34 (5.2%) 613 (94.7%) |
(1.31–71.41) | ||
|
Decreased appetite G < 2 ORR No ORR |
210 (27.7%) 549 (72.3%) |
0.47 | 0.80 |
Decreased appetite G < 2 CR No CR |
35 (4.6%) 724 (95.4%) |
0.20 | 0.16 |
|
Decreased appetite G ≥ 2 ORR No ORR |
15 (23.4%) 49 (76.6%) |
(0.44–1.46) |
Decreased appetite G ≥ 2 CR No CR |
0 (0.0%) 64 (100.0%) |
(0.01–2.61) | ||
|
Fatigue ORR No ORR |
49 (22.9%) 165 (77.1%) |
0.09 | 1.37 |
Fatigue CR No CR |
3 (1.4%) 211 (98.6%) |
0.02 | 3.90 |
|
No fatigue ORR No ORR |
176 (28.9%) 433 (71.1%) |
(0.95–1.97) |
No fatigue CR No CR |
32 (5.2%) 577 (94.7%) |
(1.18–12.87) | ||
|
Fatigue G < 2 ORR No ORR |
212 (28.1%) 542 (71.9%) |
0.10 | 0.59 |
Fatigue G < 2 CR No CR |
35 (4.6%) 719 (95.3%) |
0.18 | 0.14 |
|
Fatigue G ≥ 2 ORR No ORR |
13 (18.8%) 56 (81.1%) |
(0.32–1.11) |
Fatigue G ≥ 2 CR No CR |
0 (0.0%) 69 (100.0%) |
(0.01–2.40) | ||
|
Proteinuria ORR No ORR |
78 (32.0%) 166 (68.0%) |
0.05 | 0.72 |
Proteinuria CR No CR |
13 (5.3%) 231 (94.7%) |
0.32 | 0.70 |
|
No proteinuria ORR No ORR |
147 (25.4%) 432 (74.6%) |
(0.52–1.00) |
No proteinuria CR No CR |
22 (3.8%) 557 (96.2%) |
(0.35–1.42) | ||
|
Proteinuria G < 2 ORR No ORR |
183 (26.9%) 498 (73.1%) |
0.51 | 1.14 |
Proteinuria G < 2 CR No CR |
31 (4.5%) 650 (95.4%) |
0.36 | 0.61 |
|
Proteinuria G ≥ 2 ORR No ORR |
42 (29.6%) 100 (70.4%) |
(0.77–1.70) |
Proteinuria G ≥ 2 CR No CR |
4 (2.8%) 138 (97.2%) |
(0.21–1.75) | ||
|
Hypertension ORR No ORR |
71 (31.7%) 153 (68.3%) |
0.09 | 0.74 |
Hypertension CR No CR |
12 (5.3%) 212 (94.6%) |
0.34 | 0.70 |
|
No hypertension ORR No ORR |
154 (25.7%) 445 (74.3%) |
(0.53–1.04) |
No hypertension CR No CR |
23 (3.8%) 576 (96.2%) |
(0.34–1.44) | ||
|
Hypertension G < 2 ORR No ORR |
179 (26.9%) 485 (73.0%) |
0.61 | 1.10 |
Hypertension G < 2 CR No CR |
27 (4.1%) 637 (95.9%) |
0.59 | 1.25 |
|
Hypertension G ≥ 2 ORR No ORR |
46 (28.9%) 113 (71.1%) |
(0.75–1.62) |
Hypertension G ≥ 2 CR No CR |
8 (5.0%) 151 (95.0%) |
(0.56–2.81) | ||
|
Immunotoxicity ORR No ORR |
43 (38.7%) 68 (61.3%) |
< 0.01 | 0.54 |
Immunotoxicity CR No CR |
6 (5.7%) 105 (94.6%) |
0.52 | 0.74 |
|
No immunotoxicity ORR No ORR |
182 (25.6%) 530 (74.4%) |
(0.36–0.82) |
No immunotoxicity CR No CR |
29 (26.1%) 683 (95.9%) |
(0.30–1.83) | ||
|
Immunotoxicity G < 2 ORR No ORR |
210 (27.2%) 563 (72.8%) |
0.66 | 1.15 |
Immunotoxicity G < 2 CR No CR |
34 (4.4%) 739 (95.6%) |
0.43 | 0.44 |
|
Immunotoxicity G ≥ 2 ORR No ORR |
15 (30.0%) 35 (70.0%) |
(0.62–2.15) |
Immunotoxicity G ≥ 2 CR No CR |
1 (2.0%) 49 (98.0%) |
(0.06–3.31) | ||
|
Diarrhea ORR No ORR |
15 (22.4%) 52 (77.6%) |
0.34 | 1.33 |
Diarrhea CR No CR |
2 (3.0%) 65 (97.0%) |
0.59 | 1.48 |
|
No diarrhea ORR No ORR |
210 (27.8%) 546 (72.2%) |
(0.73–2.42) |
No diarrhea CR No CR |
33 (4.4%) 723 (95.6%) |
(0.35–6.32) | ||
|
Diarrhea G < 2 ORR No ORR |
222 (27.6%) 582 (72.4%) |
0.26 | 0.49 |
Diarrhea G < 2 CR No CR |
35 (4.3%) 769 (95.6%) |
0.68 | 0.55 |
|
Diarrhea G ≥ 2 ORR No ORR |
3 (15.8%) 16 (84.2%) |
(0.14–1.70) |
Diarrhea G ≥ 2 CR No CR |
0 (0.0%) 19 (100.0%) |
(0.03–9.39) | ||
|
Hypothyroidism ORR No ORR |
18 (40.9%) 26 (59.1%) |
0.04 | 0.52 |
Hypothyroidism CR No CR |
2 (4.5%) 42 (95.4%) |
0.92 | 0.93 |
|
No hypothyroidism ORR No ORR |
207 (26.6%) 572 (73.4%) |
(0.28–0.97) |
No hypothyroidism CR No CR |
33 (4.2%) 746 (95.8%) |
(0.21–4.00) | ||
|
Hypothyroidism G < 2 ORR No ORR |
212 (26.7%) 581 (73.3%) |
0.05 | 2.09 |
Hypothyroidism G < 2 CR No CR |
33 (4.2%) 760 (95.8%) |
0.51 | 1.64 |
|
Hypothyroidism G ≥ 2 ORR No ORR |
13 (43.3%) 17 (56.7%) |
(1.00–4.39) |
Hypothyroidism G ≥ 2 CR No CR |
2 (6.7%) 28 (93.3%) |
(0.37–7.20) | ||
|
Other toxicity ORR No ORR |
50 (30.5%) 114 (69.5%) |
0.31 | 0.82 |
Other toxicity CR No CR |
8 (4.9%) 156 (95.1%) |
0.66 | 0.83 |
|
No other toxicity ORR No ORR |
175 (26.5%) 484 (73.4%) |
(0.57–1.19) |
No other toxicity CR No CR |
27 (4.1%) 632 (95.9%) |
(0.37–1.87) | ||
|
Other toxicity G < 2 ORR No ORR |
191 (27.0%) 517 (73.0%) |
0.56 | 1.14 |
Other toxicity G < 2 CR No CR |
30 (4.2%) 678 (95.8%) |
0.96 | 1.03 |
|
Other toxicity G ≥ 2 ORR No ORR |
34 (29.6%) 81 (70.4%) |
(0.74–1.75) |
Other toxicity G ≥ 2 CR No CR |
5 (4.3%) 110 (95.6%) |
(0.39–2.70) |
The reference groups are indicated in bold
CR complete response, G grade, ORR objective response rate